X.d

Lupus - Lupus syndrome (see also Vd)

Patients with drug-induced lupus may present with serositis (See Vd). Review at PMID 20015613. Penicillamine, IFN and anti-TNF agents can cause ds-DNA-positive lupus syndrome. Drug withdrawal is followed by abatement of signs, symptoms and diminution or disappearance of anti-nuclear antibodies (ANA)

Last update : 27/02/2018
 

Causative drugs

58

Amiodarone

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.r I - Interstitial/parenchymal lung disease
I.r - Amiodarone pulmonary toxicity
I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.l II - Pulmonary edema - ARDS - Acute respiratory failure
II.l - Postoperative ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.c III - Pulmonary hemorrhage
III.c - Hemoptysis
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.i VI - Pulmonary vasculopathy
VI.i - Acute pulmonary hypertension
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi)
XI.f XI - Miscellaneous
XI.f - Pseudocyanotic skin discoloration (see also XIa, XIVa, XIVb)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.n XII - Cardiovascular involvement / toxicity
XII.n - Hypotension, shock, cardiovascular collapse
XII.p XII - Cardiovascular involvement / toxicity
XII.p - QT prolongation
XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary arterial spasm
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.g XV - Pulmonary pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa)
XV.h XV - Pulmonary pathology
XV.h - Path: Fibrotic NSIP pattern
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.j XV - Pulmonary pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XV.m XV - Pulmonary pathology
XV.m - Path: Lymphoid hyperplasia - LIP-pattern
XV.o XV - Pulmonary pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis)
XV.r XV - Pulmonary pathology
XV.r - Path: Smudged geographic necrosis
XV.ao XV - Pulmonary pathology
XV.ao - Path: Pleuritis, pleural fibrosis
XV.bt XV - Pulmonary pathology
XV.bt - Path: Histiocytic proliferation
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution
XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving
XVI.s XVI - Imaging
XVI.s - Imaging: An area or areas of involvement with high attenuation numbers or metallic density
XVI.aa XVI - Imaging
XVI.aa - Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule
XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)
XVIII.b XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.b - Eye catcher: Electron-dense area or areas of consolidation on unenhanced CT
XVIII.k XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.k - Eye-catcher: An electron-dense liver on unenhanced CT
XVIII.p XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.p - Eye-catcher: An electron-dense ('white') thyroid
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
XIX.b XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils
XIX.e XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages
XIX.f XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages in BAL, pleural fluid, or FNA
XIX.m XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.m - BAL: A normal cell differential
2

Beta-blockers

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.f IV - Airway involvement
IV.f - Severe, catastrophic asthma attack (can be fatal)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening/fibrosis - Fibrothorax
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.w VI - Pulmonary vasculopathy
VI.w - Worsening of preexisting PHTn
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Ventilatory depression-Hypoventilation (may cause ARF). See also XIe
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.y X - Systemic conditions, syndromes and reactions
X.y - Subclinical ANA positivity
XI.r XI - Miscellaneous
XI.r - Death following exposure or poisoning
XI.af XI - Miscellaneous
XI.af - Refractoriness to epineprine in case of anaphylaxis
XII.m XII - Cardiovascular involvement / toxicity
XII.m - Cardiac/cardiopulmonary arrest
2

Carbamazepine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.b VII - Mediastinal involvement
VII.b - Lymphadenopathy with reactive changes
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
2

Chemotherapy (antineoplastic)

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary opacities
I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules
I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP)
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.x I - Interstitial/parenchymal lung disease
I.x - Pleuroparenchymal fibroelastosis (PPFE)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis
I.ad I - Interstitial/parenchymal lung disease
I.ad - Radiation recall pneumonitis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
II.c II - Pulmonary edema - ARDS - Acute respiratory failure
II.c - ARDS and the hemolytic-uremic syndrome (HUS)
II.d II - Pulmonary edema - ARDS - Acute respiratory failure
II.d - Pulmonary edema, cardiogenic
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.c VI - Pulmonary vasculopathy
VI.c - Pulmonary veno-occlusive disease
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.h VII - Mediastinal involvement
VII.h - Pneumomediastinum
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.f IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.f - Hiccup
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
IX.o IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.o - Pneumorachis
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.n X - Systemic conditions, syndromes and reactions
X.n - Tumor lysis syndrome (TLS)
XI.b XI - Miscellaneous
XI.b - Chest pain (acute - subacute)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XI.w XI - Miscellaneous
XI.w - Cavitation/necrosis of lung tumor or metastases
XII.b XII - Cardiovascular involvement / toxicity
XII.b - Valvular heart disease and/or dysfunction
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.f XII - Cardiovascular involvement / toxicity
XII.f - Cardiomyopathy (acute, subacute, chronic)
XII.g XII - Cardiovascular involvement / toxicity
XII.g - Myocardial ischemia, coronary artery disease, myocardial infarction
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer
XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endothoracic)
XIII.d XIII - Neoplastic conditions
XIII.d - Malignant mesothelioma (pleural, pericardial)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.i XV - Pulmonary pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells)
XV.l XV - Pulmonary pathology
XV.l - Path: Pulmonary fibrosis, unclassifiable
XV.ak XV - Pulmonary pathology
XV.ak - Path: Pulmonary veno-occlusive disease (PVOD)
XV.am XV - Pulmonary pathology
XV.am - Path: Thrombosis in pulmonary arterioles/venules
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)
XVI.af XVI - Imaging
XVI.af - Imaging: Lung cysts or bullae (see also XVI ah/bf)
XVI.bf XVI - Imaging
XVI.bf - Imaging: Tumoral cavitation
XVI.bl XVI - Imaging
XVI.bl - Imaging: Avid lung uptake on PET-scan
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.j XVII - Infections & related conditions
XVII.j - Mucormycosis (pulmonary, tracheobronchial or systemic)
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.af XVII - Infections & related conditions
XVII.af - Reactivation of a prior pulmonary infection (TB, melioidosis)
5

Etanercept

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.q I - Interstitial/parenchymal lung disease
I.q - Nodules in lung parenchyma (a.k.a. nodulosis)
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apneas
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XI.ad XI - Miscellaneous
XI.ad - Granulomas on tattoo edges
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.ba XV - Pulmonary pathology
XV.ba - Path: Granulomatous lymphadenopathy
XVII.a XVII - Infections & related conditions
XVII.a - Pneumonia - Respiratory tract infection
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
1

Hydralazine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
III.b III - Pulmonary hemorrhage
III.b - Pneumorenal syndrome
III.d III - Pulmonary hemorrhage
III.d - Alveolar hemorrhage, diffuse, ANCA-positive or related
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc)
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
VIII.c VIII - Upper, central, large airway involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma
VIII.h VIII - Upper, central, large airway involvement
VIII.h - Vocal cord dysfunction, adduction, closure
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative)
X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ak X - Systemic conditions, syndromes and reactions
X.ak - Dual MPO-/PR3-ANCA systemic disease/vasculitis
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.k XII - Cardiovascular involvement / toxicity
XII.k - Pericardial thickening - Constrictive pericarditis
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
3

Immune checkpoint inhibitors (ICPI) - ICPI combinatorial therapy

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.am X - Systemic conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity
X.aw X - Systemic conditions, syndromes and reactions
X.aw - Connective tissue disease
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.b XV - Pulmonary pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.d XV - Pulmonary pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Infliximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD or pulmonary fibrosis (Hamman-Rich syndrome)
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
III.a III - Pulmonary hemorrhage
III.a - Diffuse alveolar hemorrhage (DAH)
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus)
VI.a VI - Pulmonary vasculopathy
VI.a - Pulmonary embolism - Venous thromboembolism
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.s X - Systemic conditions, syndromes and reactions
X.s - Pulmonary/systemic vasculitis/polyangiitis (ANCA-positive)
X.ah X - Systemic conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (w/wo ANCA) or flare of
X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass shadowing/opacities (GGO)
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization
XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia
XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous mycobacterial infection
XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia
XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia
XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary)
XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus neoformans pulmonary infection
XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation)
XVII.ac XVII - Infections & related conditions
XVII.ac - Actinomycosis
2

Interferon alpha/beta

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (A pattern consistent with)
I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis
II.a II - Pulmonary edema - ARDS - Acute respiratory failure
II.a - Pulmonary edema, noncardiogenic (NCPE)
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
IV.a IV - Airway involvement
IV.a - Bronchospasm - Asthma
IV.d IV - Airway involvement
IV.d - Cough (lone)
IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VI.b VI - Pulmonary vasculopathy
VI.b - Pulmonary arterial hypertension
VI.d VI - Pulmonary vasculopathy
VI.d - Pulmonary vasculitis or capillaritis
VI.f VI - Pulmonary vasculopathy
VI.f - The hemolytic and uremic syndrome (HUS). See also under Xaf
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
VIII.a VIII - Upper, central, large airway involvement
VIII.a - Angioedema (may cause UAO & asphyxia)
X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome
X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary/vascular leak syndrome (CLS) (see also under Xr)
X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd)
X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis
X.j X - Systemic conditions, syndromes and reactions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like, granulomatous thoracic and/or extrathoracic reaction
X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF)
XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis)
XV.a XV - Pulmonary pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib)
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XV.e XV - Pulmonary pathology
XV.e - Path: ILD with a granulomatous component (see also Im)
XV.f XV - Pulmonary pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
XV.k XV - Pulmonary pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern)
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
1